30

Nanjing Hicin Pharmaceutical Co LtdSHE 300584 Stock Report

Last reporting period 30 Sep, 2023

Updated 06 Nov, 2024

Last price

Market cap $B

0.182

Micro

Exchange

XSHE - Shenzhen Stock Exchange

300584.SZ Stock Analysis

30

Avoid

Based on Eyestock quantitative analysis, 300584.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

45/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-52.1 %

Greatly overvalued

Market cap $B

0.182

Dividend yield

0.32 %

Shares outstanding

120 B

Nanjing Hicin Pharmaceutical Co., Ltd. engages in the manufacture, research and development of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu and currently employs 563 full-time employees. The company went IPO on 2017-01-12. The firm's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.

View Section: Eyestock Rating